NASDAQ:GILD • US3755581036
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for GILEAD SCIENCES INC (GILD).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-10 | Jefferies | Initiate | Buy |
| 2026-02-23 | Needham | Reiterate | Buy -> Buy |
| 2026-02-20 | Barclays | Initiate | Equal-Weight |
| 2026-02-11 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2026-02-11 | ScotiaBank | Maintains | Sector Outperform -> Sector Outperform |
| 2026-02-11 | Needham | Maintains | Buy -> Buy |
| 2026-02-11 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2026-02-11 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2026-02-11 | Truist Securities | Maintains | Buy -> Buy |
| 2026-01-27 | Truist Securities | Maintains | Buy -> Buy |
| 2026-01-27 | Citigroup | Maintains | Buy -> Buy |
| 2026-01-26 | UBS | Maintains | Buy -> Buy |
| 2026-01-13 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2026-01-07 | Citigroup | Maintains | Buy -> Buy |
| 2025-12-12 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-12-10 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-11-13 | ScotiaBank | Initiate | Sector Outperform |
| 2025-11-13 | Needham | Maintains | Buy -> Buy |
| 2025-11-03 | Truist Securities | Reiterate | Buy -> Buy |
| 2025-10-31 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2025-10-31 | Needham | Reiterate | Buy -> Buy |
| 2025-10-31 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2025-10-31 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-10-31 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-10-23 | TD Cowen | Maintains | Buy -> Buy |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 27.116B -0.60% | 28.754B 6.04% | 29.443B 2.40% | 30.822B 4.68% | 32.702B 6.10% | 34.426B 5.27% | 36.556B 6.19% | 38.912B 6.44% | 39.628B 1.84% | 39.065B -1.42% | 39.292B 0.58% | |
| EBITDA YoY % growth | 12.555B -6.88% | 13.595B 8.28% | 14.534B 6.91% | 16.007B 10.13% | 17.305B 8.11% | 18.645B 7.74% | 21.269B 14.07% | 22.595B 6.23% | 22.572B -0.10% | 22.841B 1.19% | 25.496B 11.62% | |
| EBIT YoY % growth | 9.862B -13.34% | 10.828B 9.80% | 11.774B 8.74% | 14.476B 22.95% | 15.918B 9.96% | 17.188B 7.98% | 18.764B 9.17% | 20.282B 8.09% | 21.038B 3.73% | 20.814B -1.06% | 21.332B 2.49% | |
| Operating Margin | 36.37% | 37.66% | 39.99% | 46.97% | 48.68% | 49.93% | 51.33% | 52.12% | 53.09% | 53.28% | 54.29% | |
| EPS YoY % growth | 7.04 -3.16% | 4.61 -34.52% | 8.15 76.79% | 8.84 8.46% | 9.82 11.15% | 10.68 8.75% | 12.10 13.24% | 13.18 8.96% | 13.62 3.31% | 13.53 -0.66% | 13.95 3.10% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | 1.94 7.14% | 2.14 6.63% | 2.42 -1.90% | 2.42 29.89% |
| Revenue Q2Q % growth | 7.05B 5.74% | 7.567B 6.85% | 7.876B 1.38% | 8.306B 4.81% |
| EBITDA Q2Q % growth | 3.409B 4.57% | 4.165B 0.97% | 4.453B 2.25% | 4.59B -19.70% |
| EBIT Q2Q % growth | 3.171B 23.67% | 3.523B 28.67% | 3.87B 10.13% | 3.826B 29.43% |
All data in USD
38 analysts have analysed GILD and the average price target is 159.01 USD. This implies a price increase of 12.55% is expected in the next year compared to the current price of 141.29.
GILEAD SCIENCES INC (GILD) will report earnings on 2026-04-22.
The consensus EPS estimate for the next earnings of GILEAD SCIENCES INC (GILD) is 1.94 USD and the consensus revenue estimate is 7.05B USD.
The consensus rating for GILEAD SCIENCES INC (GILD) is 81.0526 / 100 . This indicates that analysts generally have a positive outlook on the stock.